Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple blood test outsmart deadly fungal infections in blood cancer?

NCT ID NCT07763184

Diagnosis Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This study is testing whether a blood test called metagenomic next-generation sequencing (mNGS) can accurately diagnose invasive fungal disease in people with blood cancers. These patients are at high risk for such infections, which are often hard to detect and can become severe. The trial will measure how sensitive and specific the test is compared to standard methods, potentially offering a faster and more comprehensive way to identify the infection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
metagenomic next-generation sequencing (mNGS) of peripheral blood
What this could lead to
If successful, this could lead to faster and more accurate diagnosis of invasive fungal infections in blood cancer patients, potentially improving treatment outcomes.
What could go wrong
This is a small, early-stage study. The test may not be accurate enough or may not work for all types of fungal infections. There is also a risk of false positives or negatives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population for this research consists of patients with hematological malignancies who are suspected of having IFD.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntarily signed the Informed Consent Form (ICF); * Diagnosed with a hematological malignancy and receiving necessary treatment according to clinical medical orders; * Presenting with clinical symptoms, signs, or imaging features suspected of IFD. Clinical symptoms or signs include fever, cough, expectoration, chest pain, skin and soft tissue infectious lesions, or symptoms related to other deep tissue involvement. Imaging features vary depending on the site of infection, including: if involving the lower respiratory tract/lungs, a CT scan showing at least the presence of dense, well-defined lesions (with or without a halo sign), air crescent sign, cavity, wedge-shaped/segmental or lobar consolidations, reversed halo sign, etc.; if involving the central nervous system (CNS), an MRI/CT scan indicating meningeal enhancement; or corresponding imaging features for the involvement of other deep tissues. Exclusion Criteria: * Unable to undergo necessary conventional microbiological testing or imaging examinations; * Deemed unsuitable to participate in this study by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hematological malignancies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm Invasive Fungal Infections systemic mycosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hematological malignancies Invasive fungal disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.